Duration of response and progression-free survival in patients with cHL treated with pembrolizumab and vorinostat. DOR in all responders (A), responders stratified as being anti–PD-1 naive/sensitive vs refractory (B); PFS in all patients (C), and patients stratified as being anti–PD-1 naive/sensitive vs refractory (D).